Strategies for mitigating an influenza pandemic

Nature

Volumn 442, Issue 7101, 2006, Pages 448-452

  Ferguson, Neil M ^a   Cummings, Derek A T ^b   Fraser, Christophe ^a   Cajka, James C ^c   Cooley, Philip C ^c   Burke, Donald S ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER SIMULATION; CONTAMINATION; DRUG PRODUCTS; MATHEMATICAL MODELS; VACCINES; VIRUSES;

PANDEMIC STRAIN; PROPHYLAXIS;

HEALTH CARE;

ANTIVIRUS AGENT; INFLUENZA VACCINE;

ANTIBIOTICS; COST-BENEFIT ANALYSIS; DISEASE CONTROL; EPIDEMIC; INFECTIOUS DISEASE; INFLUENZA; MITIGATION; NUMERICAL MODEL; PUBLIC HEALTH; SIMULATION; VACCINATION;

ARTICLE; DRUG EFFICACY; EPIDEMIC; HEALTH CARE POLICY; HOUSEHOLD; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MATHEMATICAL ANALYSIS; NONHUMAN; PANDEMIC; PATIENT CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; SCHOOL; SIMULATION; SYMPTOM; TRAVEL; VIRUS TRANSMISSION; WORKPLACE; CLASSIFICATION; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DRUG EFFECT; FAMILY SIZE; IMMUNOLOGY; INCIDENCE; INFLUENZA VIRUS A H5N1; LEGAL ASPECT; PHYSIOLOGY; POLICY; PREMEDICATION; SELF MEDICATION; THEORETICAL MODEL; TIME; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; VIROLOGY;

EURASIA; EUROPE; NORTH AMERICA; UNITED KINGDOM; UNITED STATES; WESTERN EUROPE;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FAMILY CHARACTERISTICS; GREAT BRITAIN; HUMANS; INCIDENCE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, THEORETICAL; PREMEDICATION; PUBLIC POLICY; QUARANTINE; SCHOOLS; SELF MEDICATION; TIME FACTORS; TRAVEL; TREATMENT OUTCOME; UNITED STATES;

EID: 33745836878     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04795     Document Type: Article

References (24)

1. World Health Organisation. WHO global influenza preparedness plan. 〈http://www.who.int/csr/resources/publications/influenza/GIP_2005_5Eweb. pdf〉 (2005).
2. Ferguson, N. M., Donnelly, C. A. & Anderson, R. M. Transmission intensity and impact of control policies on the foot and mouth epidemic in Great Britain. Nature 413, 542-548 (2001).
3. Keeling, M. J. et al. Dynamics of the 2001 UK foot and mouth epidemic: stochastic dispersal in a heterogeneous landscape. Science 294, 813-817 (2001).
4. Riley, S. et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: Impact of public health interventions. Science 300, 1961-1966 (2003).
5. Lipsitch, M. et al. Transmission dynamics and control of severe acute respiratory syndrome. Science 300, 1966-1970 (2003).
6. Ferguson, N. M. et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437, 209-214 (2005).
7. Longini, I. M. Jr et al. Containing pandemic influenza at the source. Science 309, 1083-1087 (2005).
8. Oakridge National Laboratory. Landscan global population data. 〈http://www.ornl.gov/sci/gist/landscan〉 (2003).
9. Anderson, R. M. & May, R. M. Infectious Diseases of Humans; Dynamics and Control (Oxford Univ. Press, Oxford, 1991).
10. Chotpitayasunondh, T. et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg. Infect. Dis. 11, 201-209 (2005).
11. The Writing Committee of the WHO Consultation on Human Influenza A/H5N1. Current concepts - Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353, 1374-1385 (2005).
12. World Health Organisation Writing Group. Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg. Infect. Dis. 12, 88-94 (2006).
13. Lo, J. Y. et al. Respiratory infections during SARS outbreak, Hong Kong, 2003. Emerg. Infect. Dis. 11, 1738-1741 (2005).
14. Bell, D. M. Public health interventions and SARS spread, 2003. Emerg. Infect. Dis. 10, 1900-1906 (2004).
15. Hufnagel, L., Brockmann, D. & Geisel, T. Forecast and control of epidemics in globalized world. Proc. Natl Acad. Sci. USA 101, 15124-15129 (2004).
16. World Health Organisation Writing Group, Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg. Infect. Dis. 12, 81-87 (2006).
17. Hong Kong International Airport. 〈http://www.hongkongairport.com/ eng/aboutus/statistics.html〉 (2003).
18. Gani, R. et al. Potential impact of antiviral drug use during influenza pandemic. Emerg. Infect. Dis. 11, 1355-1362 (2005).
19. Coombes, R. UK stocks up on antiviral drug to tackle flu outbreak. Br. Med. J. 330, 495 (2005).
20. Ferguson, N. M., Mallett, S., Jackson, H., Roberts, N. & Ward, P. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J. Antimicrob. Chemother. 51, 977-990 (2003).
21. Longini, I. M. J., Koopman, J. S., Monto, A. S. & Fox, J. P. Estimating household and community transmission parameters for influenza. Am. J. Epidemiol. 115, 736-751 (1982).
22. Cauchemez, S., Carrat, F., Viboud, C., Valleron, A. J. & Boelle, P. Y. A. Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. Stat. Med. 23, 3469-3487 (2004).
23. Ferguson, N. M. et al. Planning for smallpox outbreaks. Nature 425, 681-685 (2003).
24. Ferguson, N. M., Fraser, C., Donnelly, C. A., Ghani, A. C. & Anderson, R. M. Public health risk from the avian H5N1 influenza epidemic. Science 304, 968-969 (2004).